Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Other Neuroendocrine Carcinoma”

100 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 100 results

Early research (Phase 1)UnknownNCT02457650
What this trial is testing

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Who this might be right for
Bladder CarcinomaBreast CancerEsophagus Carcinoma+7 more
Shenzhen Second People's Hospital 36
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Not applicableNo Longer AvailableNCT01980732
What this trial is testing

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Who this might be right for
Carcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors
Andrei Iagaru
Early research (Phase 1)Study completedNCT01048892
What this trial is testing

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Who this might be right for
Adrenocortical CarcinomaGastrointestinal Carcinoid TumorKidney Cancer+3 more
Children's Oncology Group 22
Not applicableLooking for participantsNCT00001238
What this trial is testing

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Who this might be right for
Kidney CancerUrologic Malignant DisordersRenal Cell Carcinoma+2 more
National Cancer Institute (NCI) 5,000
Testing effectiveness (Phase 2)Study completedNCT03207347
What this trial is testing

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Who this might be right for
MesotheliomaUveal MelanomaRenal Cell Carcinoma+1 more
University of Florida 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Early research (Phase 1)Study completedNCT02475213
What this trial is testing

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Who this might be right for
MelanomaHead and Neck CancerNon Small Cell Lung Cancer+1 more
MacroGenics 146
Not applicableLooking for participantsNCT07072143
What this trial is testing

An International Study on Pediatric Patients With Rare Tumors.

Who this might be right for
Paraganglioma/ PhaeochromocytomaMelanoma and Other Malignant Neoplasms of SkinGastrointestinal Stromal Tumor (GIST)+11 more
Azienda Ospedaliera di Padova 6,250
Early research (Phase 1)Study completedNCT02857270
What this trial is testing

LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Who this might be right for
Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung Cancer+1 more
Eli Lilly and Company 210
Testing effectiveness (Phase 2)Active Not RecruitingNCT04701307
What this trial is testing

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Who this might be right for
Lung Small Cell CarcinomaNeuroendocrine CarcinomaStage III Lung Cancer AJCC v8+3 more
M.D. Anderson Cancer Center 48
Not applicableStudy completedNCT00428220
What this trial is testing

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerMetastatic Castration Resistant Prostate Cancer+9 more
Pfizer 223
Testing effectiveness (Phase 2)Study completedNCT02819843
What this trial is testing

T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Who this might be right for
MelanomaMerkel Cell CarcinomaOther Solid Tumors
Memorial Sloan Kettering Cancer Center 19
Testing effectiveness (Phase 2)UnknownNCT05675605
What this trial is testing

TY-1091 in Patients With Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+1 more
TYK Medicines, Inc 248
Early research (Phase 1)Study completedNCT00003597
What this trial is testing

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Who this might be right for
Cancer
Children's Oncology Group 16
Not applicableUnknownNCT03517332
What this trial is testing

Circulating Tumor DNA Exposure in Peripheral Blood

Who this might be right for
Colorectal CancerPancreatic AdenocarcinomaGastric Cancer+8 more
Quantgene Inc. 10,000
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192
Testing effectiveness (Phase 2)Study completedNCT04010357
What this trial is testing

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Who this might be right for
Small-cell Lung CancerLarge Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Small Cell Carcinoma
Case Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)Looking for participantsNCT06090266
What this trial is testing

OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Who this might be right for
CancerTumor, SolidMalignant Neoplasm+4 more
OncoResponse, Inc. 168
Early research (Phase 1)Active Not RecruitingNCT05907304
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 86
Next Page